Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis

• Main Authors: Richard G. Pearson (Author), Tahir Masud (Author), Elaine Blackshaw (Author), Andrew Naylor (Author), Michael Hinchcliffe (Author), Kirk Jeffery (Author), Faron Jordan (Author), Anjumn Shabir-Ahmed (Author), Gareth King (Author), Andrew L. Lewis (Author), Lisbeth Illum (Author), Alan C. Perkins (Author)
• Format: Book
• Published: MDPI AG, 2019-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Nasal delivery of large peptides such as parathyroid 1-34 (PTH 1-34) can benefit from a permeation enhancer to promote absorption across the nasal mucosa into the bloodstream. Previously, we have published an encouraging bioavailability (78%), relative to subcutaneous injection in a small animal pre...